Learn More About Janssen's Phase 3 COVID-19 Vaccine Candidate Study Here
Learn More
Press Release Archive
-
Johnson & Johnson Prepares to Resume Phase 3 ENSEMBLE Trial of its Janssen COVID-19 Vaccine Candidate in the U.S.Johnson & Johnson Prepares to Resume Phase 3 ENSEMBLE Trial of its Janssen COVID-19 Vaccine Candidate in the U.S.
-
Johnson & Johnson to Participate in the Credit Suisse 29th Annual Virtual Healthcare ConferenceJohnson & Johnson to Participate in the Credit Suisse 29th Annual Virtual Healthcare Conference
-
Johnson & Johnson Reports 2020 Third-Quarter ResultsJohnson & Johnson Reports 2020 Third-Quarter Results
· Sales of $21.1 billion reflecting an overall and operational increase of 1.7%*, and adjusted operational increase of 2.0%* despite the estimated negative impact of the COVID-19 pandemic
· EPS of $1.33 increased 101.5%; adjusted EPS of $2.20 increased 3.8%*
· Company increasing guidance for Full Year Reported Sales by $1.0 billion and Adjusted EPS by $0.15 driven by the strength of the recovery and strong underlying business fundamentals -
Statement on Opioid ResolutionStatement on Opioid Resolution
-
Champions of Science: Breaking the Stigma of Mental IllnessChampions of Science: Breaking the Stigma of Mental IllnessJoin us for a special virtual event celebrating the champions who are helping to eliminate stigma and improve mental healthcare in communities around the world
-
Johnson & Johnson Announces European Commission Approval of Agreement to Supply 200 Million Doses of Janssen’s COVID-19 Vaccine CandidateJohnson & Johnson Announces European Commission Approval of Agreement to Supply 200 Million Doses of Janssen’s COVID-19 Vaccine CandidateAgreement provides option for European Union Member States to secure up to 200 million additional doses for a total of up to 400 million doses
-
Johnson & Johnson Completes Acquisition of Momenta Pharmaceuticals, Inc.Johnson & Johnson Completes Acquisition of Momenta Pharmaceuticals, Inc.Acquisition broadens Janssen’s leadership in autoimmune diseases and provides a major catalyst for sustained growth
-
SIMPONI ARIA® (golimumab) Approved by the U.S. Food and Drug Administration for Active Polyarticular Juvenile Idiopathic Arthritis and Extension of Its Active Psoriatic Arthritis Indication in Patients 2 Years of Age and OlderSIMPONI ARIA® (golimumab) Approved by the U.S. Food and Drug Administration for Active Polyarticular Juvenile Idiopathic Arthritis and Extension of Its Active Psoriatic Arthritis Indication in Patients 2 Years of Age and OlderSIMPONI ARIA is the first and only fully human anti-tumor necrosis factor (TNF)-alpha biologic agent administered by intravenous (IV) infusion approved for pediatric use in both active polyarticular juvenile idiopathic arthritis (pJIA) and active psoriatic arthritis (PsA)Phase 3 GO-VIVA clinical trial adds to the growing body of evidence for SIMPONI ARIASIMPONI ARIA is a 30-minute IV infusion administered by a health care professional once every eight weeks after starter doses at weeks 0 and 4
-
Janssen Submits New Drug Application (NDA) to U.S. FDA for UPTRAVI® (selexipag) Injection for Intravenous Use to Treat Pulmonary Arterial Hypertension (PAH)Janssen Submits New Drug Application (NDA) to U.S. FDA for UPTRAVI® (selexipag) Injection for Intravenous Use to Treat Pulmonary Arterial Hypertension (PAH)
-
(This statement was updated on October 4, 2020 to include additional information)
Johnson & Johnson Posts Interim Results from Phase 1/2a Clinical Trial of its Janssen COVID-19 Vaccine Candidate(This statement was updated on October 4, 2020 to include additional information)
Johnson & Johnson Posts Interim Results from Phase 1/2a Clinical Trial of its Janssen COVID-19 Vaccine CandidateInterim analysis from Phase 1/2a First-in-Human trial supports further clinical development of investigational vaccine candidate JNJ-78436735 (also known as Ad26.COV2.S)